Plain Language Summary of a Phase 2b Randomized Controlled Trial of Ecopipam and Its 12-Month Open-Label Extension in Children and Adolescents With Tourette Syndrome
What is this summary about? The purpose of this summary is to explain the results from two studies that looked at the safety and effects of an investigational drug called ecopipam. "Investigational" means that the drug has not been approved by the United States Food and Drug Administration (FDA) yet. The studies tested if ecopipam could safely improve symptoms and quality of life in children and adolescents with Tourette syndrome. Please note that ecopipam is not currently approved to treat Tourette syndrome.
Authors
- George B. Karkanias (ORCID: https://orcid.org/0009-0006-3510-5816)
- Timothy Cunniff
- Meredith Miller
- Stephen P. Wanaski
- Frederick E. Munschauer
- David J. B. Kim
- Sarah D. Atkinson
- Donald L. Gilbert
Institutions
- Cincinnati Children's Hospital Medical Center (US)
- Paragon Genomics (United States) (US)
- Nextomics Biosciences (China) (CN)
- University of Cincinnati (US)
- University of Cincinnati Medical Center (US)
Publication Details
- Journal
- Therapeutic Advances in Neurological Disorders
- Published
- 2026-02-26
- DOI
- https://doi.org/10.1177/17562864261424987
- Primary Topic
- Obsessive-Compulsive Spectrum Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00